Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2026 08:15 ET | Source: Ocean Power Technologies, Inc.

Ocean Power Technologies Advances Offshore Charging and Autonomous Operations for Maritime Drones

MONROE TOWNSHIP, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in innovative and cost-effective low-carbon marine...
May 07, 2026 08:05 ET | Source: SNS Insider pvt ltd

Brain Pacemaker Market Size is Expected to Reach USD 5.97 Billion by 2035; Industry Growth is Propelling Owing to Surging Incidence of Neurological Disorders | SNS Insider

Brain Pacemaker Market grows with rising neurological disorders, DBS adoption, AI-enabled neurostimulation, and minimally invasive therapies.
May 07, 2026 08:01 ET | Source: Ardelyx, Inc.

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...
May 07, 2026 08:00 ET | Source: ArriVent BioPharma, Inc.

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026...
May 07, 2026 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and...
May 07, 2026 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global...
May 07, 2026 08:00 ET | Source: ALX Oncology

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the...
May 07, 2026 08:00 ET | Source: Prime Medicine, Inc.

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue...
May 07, 2026 08:00 ET | Source: Core Molding Technologies, Inc.

Core Molding Technologies Reports Fiscal 2026 First Quarter Results

COLUMBUS, Ohio, May 07, 2026 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing...
May 07, 2026 08:00 ET | Source: Filana Therapeutics, Inc.

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for...